These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 26685802)
1. MM-398 (nanoliposomal irinotecan): emergence of a novel therapy for the treatment of advanced pancreatic cancer. Carnevale J; Ko AH Future Oncol; 2016 Feb; 12(4):453-64. PubMed ID: 26685802 [TBL] [Abstract][Full Text] [Related]
2. Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer. Chiang NJ; Chang JY; Shan YS; Chen LT Expert Opin Pharmacother; 2016 Jul; 17(10):1413-20. PubMed ID: 27140876 [TBL] [Abstract][Full Text] [Related]
3. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Ko AH; Tempero MA; Shan YS; Su WC; Lin YL; Dito E; Ong A; Wang YW; Yeh CG; Chen LT Br J Cancer; 2013 Aug; 109(4):920-5. PubMed ID: 23880820 [TBL] [Abstract][Full Text] [Related]
4. Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan. Ko AH Int J Nanomedicine; 2016; 11():1225-35. PubMed ID: 27099488 [TBL] [Abstract][Full Text] [Related]
5. The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy. Passero FC; Grapsa D; Syrigos KN; Saif MW Expert Rev Anticancer Ther; 2016 Jul; 16(7):697-703. PubMed ID: 27219482 [TBL] [Abstract][Full Text] [Related]
6. Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer. Ur Rehman SS; Lim K; Wang-Gillam A Expert Rev Anticancer Ther; 2016 May; 16(5):485-92. PubMed ID: 27043737 [TBL] [Abstract][Full Text] [Related]
7. Liposomal Irinotecan in the Treatment of Refractory Pancreatic Cancer. Bien H; Mackenzie GG; Choi M Recent Pat Anticancer Drug Discov; 2016; 11(4):376-383. PubMed ID: 27480831 [TBL] [Abstract][Full Text] [Related]
8. Systemic Combination Chemotherapy in Elderly Pancreatic Cancer: a Review. Garcia G; Odaimi M J Gastrointest Cancer; 2017 Jun; 48(2):121-128. PubMed ID: 28303435 [TBL] [Abstract][Full Text] [Related]
9. Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? Aprile G; Negri FV; Giuliani F; De Carlo E; Melisi D; Simionato F; Silvestris N; Brunetti O; Leone F; Marino D; Santini D; Dell'Aquila E; Zeppola T; Puzzoni M; Scartozzi M Crit Rev Oncol Hematol; 2017 Jul; 115():1-12. PubMed ID: 28602164 [TBL] [Abstract][Full Text] [Related]
10. Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017. Cinar P; Ko AH Chin Clin Oncol; 2017 Jun; 6(3):29. PubMed ID: 28705006 [TBL] [Abstract][Full Text] [Related]
11. Irinotecan (Campto) in the treatment of pancreatic cancer. Pizzolato JF; Saltz LB Expert Rev Anticancer Ther; 2003 Oct; 3(5):587-93. PubMed ID: 14599083 [TBL] [Abstract][Full Text] [Related]
12. MM-398 achieves primary endpoint of overall survival in phase III study in patients with gemcitabine refractory metastatic pancreatic cancer. Saif MW JOP; 2014 May; 15(3):278-9. PubMed ID: 24865544 [No Abstract] [Full Text] [Related]
13. [Nanoliposomal Irinotecan in Combination with Fluorouracil and Folinic Acid, As a New Option for Second-Line Treatment in Metastatic Pancreatic Cancer]. Ueno M Gan To Kagaku Ryoho; 2020 Jun; 47(6):955-962. PubMed ID: 32541174 [TBL] [Abstract][Full Text] [Related]
14. A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors. Chiang NJ; Chao TY; Hsieh RK; Wang CH; Wang YW; Yeh CG; Chen LT BMC Cancer; 2016 Nov; 16(1):907. PubMed ID: 27871319 [TBL] [Abstract][Full Text] [Related]